Sentinel System Bridge Contract

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

FDAINTENTTOSOLESOURCEBRIDGESENTINEL2

NAICS

-

Classification Code

B537

Additional Details
Set Aside

NONE

Place of Performance

Canton, Massachusetts, UNITED STATES

SourceSAM
Documents1
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued an award notice for a bridge contract titled "Sentinel System Bridge Contract." This procurement activity is managed by the FDA Office of Acquisition and Grant Services, a federal office responsible for supporting the agency’s mission through effective contracting solutions. The primary purpose of this bridge contract is to ensure the continued operation and support of the Sentinel System, a critical infrastructure for the FDA’s post-market surveillance of medical products. The Sentinel System enables the FDA to proactively monitor the safety of regulated medical products, leveraging electronic healthcare data to identify and assess potential safety issues. The bridge contract is intended to provide uninterrupted services and maintain the integrity of the Sentinel System while the FDA transitions to a longer-term contracting solution. The scope of this procurement encompasses all necessary services to sustain the Sentinel System’s operations. This includes, but may not be limited to, system maintenance, data management, and ongoing analytical support to ensure the system’s reliability and effectiveness in monitoring medical product safety. The expected deliverables are the continued availability and functionality of the Sentinel System, timely data analysis, and comprehensive reporting to support FDA’s regulatory decisions. This contract is classified under Product Service Code B537, which pertains to specialized studies and analyses in medical and health fields. The place of performance is specified as Canton, Massachusetts, United States, indicating that the contractor’s primary activities will be based in this location. There are no set-aside requirements associated with this procurement, meaning it is not restricted to small businesses or any particular socioeconomic category. Contractors should note that this is a sole source bridge contract, as referenced in the notice description and the associated Justification and Approval (J&A) attachment, which outlines the rationale for this procurement approach. The notice remains active as of the posting date and can be accessed through the official SAM.gov portal for further details and the J&A attachment. Interested parties are encouraged to review the J&A for additional context regarding the sole source determination and specific requirements. In summary, this bridge contract represents a critical interim measure to ensure the FDA’s Sentinel System remains fully operational, supporting the agency’s mandate to protect public health through robust post-market surveillance. Contractors with expertise in medical data systems, health informatics, and regulatory support services may find this opportunity aligns with their capabilities, particularly if they have experience in maintaining complex health surveillance infrastructures.